Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

NCT02446860 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT02446860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2015
Completion date
August 31, 2018
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma